Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Inhibitory Effects of Gamimahaenggamsuk-tang on RA-related Inflammatory Responses in Cultured Fibroblast-like Synoviocytes

  • Jo Jun (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • NamGung Uk (Department of Neurophysiology, College of Oriental Medicine, Daejeon University) ;
  • Kim Soo-Myung (Department of Anatomy, College of Oriental Medicine, Daejeon University) ;
  • Kang Tak-Lim (Department of Parmacology, College of Oriental Medicine, Daejeon University) ;
  • Kim Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University)
  • Published : 2005.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Gamimahaenggamsuk-tang (GMHGST) is used for treatment of inflammatory diseases including rheumatoid arthritis (RA). Here, regulatory activity of GMHGST on RA-mediated inflammatory responses was investigated in cultured human fiDroblast-like synoviocytes (FLS), Levels of mRNAs encoding for inflammatory cytokines such as $IL-1{\beta}$, IL-6 and IL-8 and NOS-II enzyme, which had been induced by $TNF-{\alpha}$ and $IL-1{\beta}$ cotreatment, were decreased to the similar levels as those in cells treated with anti-inflammatory agent MTX. mRNA expressions of matrix metalloproteinase-3 (MMP-3) and tissue inhibitor of metalloproteinases (TIMPs) as well as intercellular adhesion molecule (ICAM) were also downregulated by increasing doses of GMHGST in activated FLS. Moreover, GMHGST appeared to protect cells by decreasing NO levels, and inhibited cell proliferation which had been induced by inflammatory stimulation by $TNF-{\alpha}$ and IL-1. These results suggest that GMHGST is effective as an inhibitory agent for regulating inflammatory responses in activated FLS.

Keywords

References

  1. Aho, K., Koskenvuo, M., Tucminen, J., Kaprio, J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol 13(5):899-902, 1986.
  2. Ahrens, D., Koch, A.E., Pope, R.M., Stein-Picarella, M., Niedbala, M.J. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 39, pp 1576-1587, 1996.
  3. Allen, J.B., Manthey, C.L., Hand, A.R. Rapid onset of synovial inflammation and hyperplasia induced by transforming growth factor beta. J. Exp. 171, pp 231-247, 1990.
  4. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, 1Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 38, pp 713-722, 1996.
  5. Aruoma, O.I. Use of DNA damage as a measure of pro-oxidant actions of antioxidant food additives and nutrient components. In: B. Halliwell and O.I. Aruorna, Editors, DNA and Free Radicals, Ellis Horwood, London, pp 315-327, 1993.
  6. Dasgupta, B., Corkill, M., Kirkham, B., Gibson, T., Panayi, G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J. Rheumatol 19, pp 22-25, 1992.
  7. Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P., Revillard, J.P. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 102, pp 322-328, 1998.
  8. Gribi, R., Tanaka, T., Harper-Summers, R, Yu, J. Expression of activin A in inflammatory arthropathies. Mol. Cell Endocrinol 180, pp 163-167, 2001.
  9. Hwang, S.Y., Kim, J.Y., Kim, K.W., Park, M.K., Moon, Y.,Kim, W.U., Kim, H.Y. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/ Akt-dependent pathways. Arthritis Res. 6, pp 120-128, 2004.
  10. Huang, W., Li, W.Q., Dehnade, F., Zafarullah, M. Tissue inhibitor of metalloproteinases-4 (TIMP-4) gene expression is increased in human osteoarthritic femoral head cartilage. J. Cell. Biochem. 85, pp 295-303, 2002.
  11. Jungel, A., Distler, J.H., Kurowska-Stolarska, M., Seemayer, C.A., Seibl, R., Forster, A., Michel, B.A., Gay, RE., Emrnrich, F., Gay, S., Distler, O. Expression of interleukin-21 receptor, but not interleukin-Zl, in synovial fibroblasts and synovial macro phages of patients with rheumatoid arthritis. Arthritis Rheum. 50, pp 1468-1476, 2004.
  12. 김호철, 이상인, 안덕균, Human monocyte의 IL-8생산억제에 미치는 류마토이드관절염 치료제로서의 오가피의 효과. 대한본초학회지. 10(1):49-58, 1996.
  13. Kirwan, J.R. The relationship between synovitis and erosions in rheumatoid arthritis. Br. J. Rheumatol, 36, pp 225-228, 1997.
  14. Kojima, F., Naraba, H., Sasaki, Y., Beppu, M., Aoki. H., Kawai, S. Prostaglandin E2 is an enhancer of interleukinlbeta-induce expression of membrane-associated prostaglandin E syntase in rheumatoid synovial fibroblasts. Arthritis Rheum. 48, pp 2819-2828, 2003.
  15. Kontoyiannis, D., Kollias, G. Fibroblast biology. Synovial fibroblasts in rheumatoid arthritis: leading role or chorus line? Arthritis Res. 2, pp 342-343, 2000.
  16. Konttinen, Y.T., Ainola, M., Valleala, H., Ma, L Ida, H., Mandelin, J., Kinne, R.W., Santavirta, S., Sorsa, T., Lopez-Orin, C., Takagi, M. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 58, pp 691-697, 1999.
  17. Kramer, I., Wilbulswas, A., Croft, D., Genot, E. Rheumatoid arthritis: targeting the proliferative fibroblast. Prog. Cell Cycle Res. 5, pp 59-70, 2003.
  18. Krause, D., Schleusser, B., Herborn, G., Rau, R Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis and Rheumatism. 43, pp 14-21, 2000.
  19. Lee, D.M., Weinblatt, M.E. Rheumatoid arthritis. Lancet. 15, pp 903-911, 2001.
  20. Manabe, N., Oda, H., Nakamura, K. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology. 38, pp 714-720, 1999.
  21. Martel-Pelletier, J., Welsch, D.J., Pelletier, J.P. Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res., Clini. Rheumatol. 15, pp 805-829, 2001.
  22. McCarey, D.W., Mclnnes, I.B., Madhok, R., Hampson, R., Scherbakov, O., Ford, I., Capell, H.A., Sattar, N. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 363, pp 2015-2021, 2004.
  23. Melnyk, V.O., Shipley, G.D., Sternfeld, M.D., Sherman, L., Rosenbaum, J.T. Synoviocytes synthesize, bind, and respond to basic fibroblast growth factor. Arthritis Rheum. 33, 493 - 500, 1990.
  24. Miranda-Cams, M.E., Balsa, A., Benito-Miguel, M., Perez de Ayala, C., Martin-Mola, E. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J. Immunol. 173, pp 1463-1476, 2004.
  25. Morel, J.C, Park, C.C., Zhu, K. Signal transduction pathways involved in rheumatoid synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-I expression. J. BioI. Chern. 38, pp 34679-34691, 2002.
  26. Mottonen, T.T. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Annals Rheum Dis. 47, pp 648-665, 1988.
  27. Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai S., Takeuchi, T., Hashimoto, J., Azuma, J., Kishimoto, T. Treatment of rheumatoid arthritis with humanized anti-interleukin-o receptor antibody. Arthritis Rheum. 50, pp 1761-1769, 2004.
  28. Ota, F., Maeshirna, A., Yamashita, S. Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. 48, pp 2442-2449, 2003.
  29. Pap, T., Muller-Ladner, D., Gay, R.E. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2, pp 361-367, 2000.
  30. Pincus, T., Callahan, L.F. What is the natural history of rheumatoid arthritis? Rheumatic Diseases Clinics of North America. 19, pp 123-151, 1993.
  31. Plant, M.J., Saklatvala, J., Borg, A.A., Hones, P.W., Dawes, P.T. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol. 21, pp 1808-1813, 1994.
  32. Ramsey, S.D., Spencer, A.C., Topolski, T.D., Belza, B., Patrick, D.L. Use of alternative therapies by older adults with osteoarthritis. Arthritis Rheum. 45, pp 222-227, 2001.
  33. Scartezzini, D., Speroni, E. Review on some plants of Indian traditional medicine with antioxidant activity. Journal of Ethnopharmacology. 71, pp 23-43, 2000.
  34. Schulz, J.B., Lindnau, J., Seyfriend, J., Dichgans, J. Glutathione oxidative stress and neuro-degeneration. European Journal of Biochemistry. 267, pp 4904-4911, 2000.
  35. Silman, A.J., MacGregor, A.J., Thomson, W., Holligan, S., Carthy, D., Farhan, A, Ollier, W.E. Twin concordance rates for rheumatoid arthritis: results from a nationwidestudy. Br J Rheumatol, 32(10):903-907, 1993.
  36. Smeets, T.J., Kraan, M.C., van Loon, M.E. Tumor necrosis factor a blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial cells. Arthritis Rheum. 48, pp 2155-2162, 2003.
  37. Stransky, G., Vernon, J., Aicher, W.K. Virus-like particles in synovial fluids from patients with rheumatoid arthritis. Br. J. Rheumatol. 32, pp 1044-1048, 1993.
  38. Tak, P.P., Thurkow, E.W., Daha, M.R., Kluin, P.M., Smeets, T.J, Meinders, A.E., Breedveld, F.C. Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol. 77(3):236-242, 1995.
  39. Wendling, D., Racadot, E., Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20, pp 259-262, 1993.
  40. Wilske, K.R., Healey, L.A. Remodeling the pyramid: a concept whose time has come. J Rheumatol. 16, pp 505-507, 1989.
  41. Yelin, E., Callahan, L. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum. 38, pp 1351-1362, 1995.